Evaluation of 18F-Fludarabine PET in Initial and Relapsed Assessment of Symptomatic Multiple Myeloma Patients

The primary objective of the study is to evaluate the utility of **18F-Fludarabine PET** imaging in the initial or relapsed assessment and therapeutic evaluation of patients with symptomatic **multiple myeloma**. This is clinically relevant as it may provide insights into the disease's metabolic activity and response to treatment, potentially guiding therapeutic decisions and improving patient outcomes.

The clinical trial involves participants diagnosed with **multiple myeloma**, a condition characterized by cancerous plasma cells in the bone marrow. The study population includes both male and female subjects, with an age range that encompasses adults and older adults. The trial does not specifically target a vulnerable population. However, the total number of participants has not been disclosed by the sponsor. The selection criteria for the trial population, as well as any lifestyle considerations such as diet or physical activity, have not been provided. Key inclusion or exclusion criteria are also not specified in the available data.

The clinical trial is designed to evaluate the efficacy of **18F-Fludarabine PET** in the assessment and therapeutic evaluation of patients with symptomatic **multiple myeloma**. This study is structured as a Phase 3 trial, which is a critical stage in clinical research aimed at confirming the effectiveness of a new intervention. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from the recruitment start date on September 7, 2022, to the anticipated end date on March 7, 2030.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This is followed by multiple follow-up visits scheduled at predetermined intervals to monitor the participants' response to the intervention and to collect necessary data. The sequence of these visits is crucial for maintaining the integrity of the trial and ensuring comprehensive data collection. The trial concludes with an end-of-study visit, where final assessments are conducted, and participants are debriefed.

The expected length of participant involvement in the trial is determined by the study protocol, which outlines the specific timeline for each phase of the trial. Participants may be subject to early termination from the study if they experience adverse effects, fail to comply with the study protocol, or withdraw consent. Such conditions are clearly defined to protect the safety and rights of the participants while maintaining the scientific rigor of the trial.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to have an estimated recruitment start date of September 7, 2022, and an estimated end date of March 7, 2030. The efficacy assessment will be conducted using predefined primary and secondary endpoints, although specific endpoints are not detailed in the provided data. The trial will follow a structured methodology to ensure the accurate measurement and analysis of efficacy parameters. The data collection and analysis will adhere to the rigorous standards expected in a Phase 3 clinical trial, ensuring the reliability and validity of the results. The trial will be conducted over a significant period, allowing for comprehensive evaluation of the treatment's efficacy.